Fibromuscular Dysplasia Companies

Latest Fibromuscular Dysplasia Companies Update

June 2023: An international cooperation agreement for the research, development, and marketing of NRX-101 for suicidal treatment-resistant bipolar disorder (S-TRBD) for worldwide markets was announced by Lotus Pharmaceuticals, a multinational pharmaceutical company; Alvogen, a privately held pharmaceuticals company based in the United States; and NRx Pharmaceuticals Inc., a clinical stage biopharmaceutical company. Upon successful completion of both the Type B meeting with the U.S. Food and Drug Administration (FDA) and a successful read-out from the ongoing Phase 2b/3 clinical trial in S-TRB, NRx will be entitled to receive an initial payment of $10 million under the terms of the agreement, which pertains to NRX-101 for the U.S. market. Upon NRX-101's FDA clearance, NRx would earn an extra $5 million. Bonus milestone payments would go up to $330 million based on specified net sales milestones.

• Alkermes Pharma Ireland Limited


• ALVOGEN


• Aspen Surgical Products, Inc.


• AstraZeneca


• B. Braun Melsungen AG


• Bayer Healthcare Pharmaceuticals Inc.


• Becton


• Dickinson and Company


• Bristol-Myers Squibb


• Dainippon Sumitomo Pharma Co.Ltd


• Ethicon, Inc.


• Merck


• Novartis


• Pfizer


• Sanofi-Aventis


• Smith & Nephew plc;


• Medtronic


• Stryker Corporation


• Watson Pharma Private Limited.